ProMetic Life Sciences receives Bioseparation Technology Leadership of the Year Award
The award acknowledges ProMetic's outstanding efforts in developing the innovative Mimetic Ligand(TM) technology that consistently delivers pure and high-yield proteins. ProMetic's Mimetic Ligand(TM) technology is a product of over 15 years of research into bioseparation. It is estimated that 50% of the cost of goods of biopharmaceuticals are related to bioseparation steps. "ProMetic's technology is cost-effective and is not capital intensive," explains Frost & Sullivan Industry Analyst Giridhar Rao. Over 40 market players including Aventis, GlaxoSmithKline, and Novo Nordisk have adopted ProMetic's revolutionary ligands technology.
With the approval of the U.S. Food and Drug Administration (FDA), the future for ProMetic's ligand technology looks bright. "FDA has not only validated the use of this technology for higher yield and purity products, but has also approved many products incorporating ProMetic's ligand technology," concludes Rao.
"We are very pleased to receive this award that formally recognizes ProMetic as a technology leader in the bioseparation field, with our Mimetic Ligand(TM) core technology and the skills of our experienced team enabling us to further improve well-established therapies and create better and more efficient technologies for new drugs and disease treatments," said Pierre Laurin, ProMetic's Chairman and CEO.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.